Lataa...
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
BACKGROUND: Dimethyl fumarate (DMF) and fingolimod (FTY) are approved oral disease-modifying therapies for relapsing multiple sclerosis (MS). Observational studies are valuable when randomized clinical trials cannot be done due to ethical or practical reasons. Two-site studies allow investigators to...
Tallennettuna:
| Julkaisussa: | Neurol Clin Pract |
|---|---|
| Päätekijät: | , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Lippincott Williams & Wilkins
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6105060/ https://ncbi.nlm.nih.gov/pubmed/30140580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000487 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|